
Merck & Co., Inc.
Rahway, USCompany profile is currently being completed.
Omistajan profiiliRobert Davis↗Business Communicatorin yritykset
Tutustu tarjousten takana oleviin yrityksiin ja löydä paikallinen kumppani.
Selaa yrityksiä

Company profile is currently being completed.
Omistajan profiiliRobert Davis↗
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. Established in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group plc, AstraZeneca specializes in the research, development, and manufacturing of prescription medicines. Its diverse portfolio addresses major diseases across oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company operates globally, with a workforce of approximately 89,900 employees as of 2025. In 2025, AstraZeneca reported revenues of US$58.739 billion, reflecting its strong market position. The company's mission is to push the boundaries of science to deliver life-changing medicines, emphasizing innovation, sustainability, and patient-centricity. AstraZeneca's global presence and commitment to research and development have solidified its role as a leader in the pharmaceutical industry.
Omistajan profiiliPascal Soriot↗
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. Established in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group plc, AstraZeneca specializes in the research, development, and manufacturing of prescription medicines. Its diverse portfolio addresses major diseases across oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company operates globally, with a workforce of approximately 89,900 employees as of 2025. In 2025, AstraZeneca reported revenues of US$58.739 billion, reflecting its strong market position. The company's mission is to push the boundaries of science to deliver life-changing medicines, emphasizing innovation, sustainability, and patient-centricity. AstraZeneca's global presence and commitment to research and development have solidified its role as a leader in the pharmaceutical industry.
Omistajan profiiliPascal Soriot↗
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. Established in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group plc, AstraZeneca specializes in the research, development, and manufacturing of prescription medicines. Its diverse portfolio addresses major diseases across oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company operates globally, with a workforce of approximately 89,900 employees as of 2025. In 2025, AstraZeneca reported revenues of US$58.739 billion, reflecting its strong market position. The company's mission is to push the boundaries of science to deliver life-changing medicines, emphasizing innovation, sustainability, and patient-centricity. AstraZeneca's global presence and commitment to research and development have solidified its role as a leader in the pharmaceutical industry.
Omistajan profiiliPascal Soriot↗
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. Established in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group plc, AstraZeneca specializes in the research, development, and manufacturing of prescription medicines. Its diverse portfolio addresses major diseases across oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company operates globally, with a workforce of approximately 89,900 employees as of 2025. In 2025, AstraZeneca reported revenues of US$58.739 billion, reflecting its strong market position. The company's mission is to push the boundaries of science to deliver life-changing medicines, emphasizing innovation, sustainability, and patient-centricity. AstraZeneca's global presence and commitment to research and development have solidified its role as a leader in the pharmaceutical industry.
Omistajan profiiliPascal Soriot↗
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. Established in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group plc, AstraZeneca specializes in the research, development, and manufacturing of prescription medicines. Its diverse portfolio addresses major diseases across oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company operates globally, with a workforce of approximately 89,900 employees as of 2025. In 2025, AstraZeneca reported revenues of US$58.739 billion, reflecting its strong market position. The company's mission is to push the boundaries of science to deliver life-changing medicines, emphasizing innovation, sustainability, and patient-centricity. AstraZeneca's global presence and commitment to research and development have solidified its role as a leader in the pharmaceutical industry.
Omistajan profiiliPascal Soriot↗
Sanofi is a global biopharmaceutical company committed to improving people's lives through innovative medicines and vaccines. With a strong presence in over 100 countries, Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Its subsidiary, Sanofi Pasteur, is the world's largest producer of vaccines. The company's mission is to chase the miracles of science to improve people's lives, addressing urgent healthcare, environmental, and societal challenges. Sanofi's market position is strengthened by its diverse portfolio and global reach, aiming to deliver compelling growth and positive impact for communities worldwide.
Omistajan profiiliBelen Garijo↗
Sanofi is a global biopharmaceutical company committed to improving people's lives through innovative medicines and vaccines. With a strong presence in over 100 countries, Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Its subsidiary, Sanofi Pasteur, is the world's largest producer of vaccines. The company's mission is to chase the miracles of science to improve people's lives, addressing urgent healthcare, environmental, and societal challenges. Sanofi's market position is strengthened by its diverse portfolio and global reach, aiming to deliver compelling growth and positive impact for communities worldwide.
Omistajan profiiliBelen Garijo↗
Sanofi is a global biopharmaceutical company committed to improving people's lives through innovative medicines and vaccines. With a strong presence in over 100 countries, Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Its subsidiary, Sanofi Pasteur, is the world's largest producer of vaccines. The company's mission is to chase the miracles of science to improve people's lives, addressing urgent healthcare, environmental, and societal challenges. Sanofi's market position is strengthened by its diverse portfolio and global reach, aiming to deliver compelling growth and positive impact for communities worldwide.
Omistajan profiiliBelen Garijo↗
Sanofi is a global biopharmaceutical company committed to improving people's lives through innovative medicines and vaccines. With a strong presence in over 100 countries, Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Its subsidiary, Sanofi Pasteur, is the world's largest producer of vaccines. The company's mission is to chase the miracles of science to improve people's lives, addressing urgent healthcare, environmental, and societal challenges. Sanofi's market position is strengthened by its diverse portfolio and global reach, aiming to deliver compelling growth and positive impact for communities worldwide.
Omistajan profiiliBelen Garijo↗
Sanofi is a global biopharmaceutical company committed to improving people's lives through innovative medicines and vaccines. With a strong presence in over 100 countries, Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Its subsidiary, Sanofi Pasteur, is the world's largest producer of vaccines. The company's mission is to chase the miracles of science to improve people's lives, addressing urgent healthcare, environmental, and societal challenges. Sanofi's market position is strengthened by its diverse portfolio and global reach, aiming to deliver compelling growth and positive impact for communities worldwide.
Omistajan profiiliBelen Garijo↗
Novartis AG is a global healthcare company headquartered in Basel, Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a presence in approximately 120 countries, Novartis reached over 300 million patients worldwide in 2025. The company's portfolio includes innovative medicines in areas such as cardiovascular diseases, oncology, and rare genetic disorders, with a strong focus on advanced therapy platforms like cell and gene therapies, RNA therapeutics, and radioligand therapy. Novartis is committed to ethical practices, transparency, and expanding access to healthcare, aiming to deliver high-value medicines that address society's most pressing health challenges. Under the leadership of CEO Vasant Narasimhan since 2018, Novartis has experienced significant growth and innovation, solidifying its position as a leader in the pharmaceutical industry.
Omistajan profiiliVasant Narasimhan↗
Novartis AG is a global healthcare company headquartered in Basel, Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a presence in approximately 120 countries, Novartis reached over 300 million patients worldwide in 2025. The company's portfolio includes innovative medicines in areas such as cardiovascular diseases, oncology, and rare genetic disorders, with a strong focus on advanced therapy platforms like cell and gene therapies, RNA therapeutics, and radioligand therapy. Novartis is committed to ethical practices, transparency, and expanding access to healthcare, aiming to deliver high-value medicines that address society's most pressing health challenges. Under the leadership of CEO Vasant Narasimhan since 2018, Novartis has experienced significant growth and innovation, solidifying its position as a leader in the pharmaceutical industry.
Omistajan profiiliVasant Narasimhan↗
Novartis AG is a global healthcare company headquartered in Basel, Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a presence in approximately 120 countries, Novartis reached over 300 million patients worldwide in 2025. The company's portfolio includes innovative medicines in areas such as cardiovascular diseases, oncology, and rare genetic disorders, with a strong focus on advanced therapy platforms like cell and gene therapies, RNA therapeutics, and radioligand therapy. Novartis is committed to ethical practices, transparency, and expanding access to healthcare, aiming to deliver high-value medicines that address society's most pressing health challenges. Under the leadership of CEO Vasant Narasimhan since 2018, Novartis has experienced significant growth and innovation, solidifying its position as a leader in the pharmaceutical industry.
Omistajan profiiliVasant Narasimhan↗
Novartis AG is a global healthcare company headquartered in Basel, Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a presence in approximately 120 countries, Novartis reached over 300 million patients worldwide in 2025. The company's portfolio includes innovative medicines in areas such as cardiovascular diseases, oncology, and rare genetic disorders, with a strong focus on advanced therapy platforms like cell and gene therapies, RNA therapeutics, and radioligand therapy. Novartis is committed to ethical practices, transparency, and expanding access to healthcare, aiming to deliver high-value medicines that address society's most pressing health challenges. Under the leadership of CEO Vasant Narasimhan since 2018, Novartis has experienced significant growth and innovation, solidifying its position as a leader in the pharmaceutical industry.
Omistajan profiiliVasant Narasimhan↗
Novartis AG is a global healthcare company headquartered in Basel, Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a presence in approximately 120 countries, Novartis reached over 300 million patients worldwide in 2025. The company's portfolio includes innovative medicines in areas such as cardiovascular diseases, oncology, and rare genetic disorders, with a strong focus on advanced therapy platforms like cell and gene therapies, RNA therapeutics, and radioligand therapy. Novartis is committed to ethical practices, transparency, and expanding access to healthcare, aiming to deliver high-value medicines that address society's most pressing health challenges. Under the leadership of CEO Vasant Narasimhan since 2018, Novartis has experienced significant growth and innovation, solidifying its position as a leader in the pharmaceutical industry.
Omistajan profiiliVasant Narasimhan↗
Lonza Group AG, founded in 1897, is a Swiss multinational company specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition industries. Headquartered in Basel, Switzerland, Lonza operates over 30 sites across Europe, North America, and Asia, employing approximately 18,000 people. The company offers a comprehensive range of services, including the development and manufacturing of biopharmaceuticals, small molecules, cell and gene therapies, and health ingredients. Lonza's mission is to transform customers' breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. The company is recognized as a pioneer and world leader in the contract development and manufacturing organization (CDMO) industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. In 2023, Lonza reported revenues of CHF 3.6 billion and a CORE EBITDA of CHF 1.1 billion.
Omistajan profiiliWolfgang Wienand↗
Lonza Group AG, founded in 1897, is a Swiss multinational company specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition industries. Headquartered in Basel, Switzerland, Lonza operates over 30 sites across Europe, North America, and Asia, employing approximately 18,000 people. The company offers a comprehensive range of services, including the development and manufacturing of biopharmaceuticals, small molecules, cell and gene therapies, and health ingredients. Lonza's mission is to transform customers' breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. The company is recognized as a pioneer and world leader in the contract development and manufacturing organization (CDMO) industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. In 2023, Lonza reported revenues of CHF 3.6 billion and a CORE EBITDA of CHF 1.1 billion.
Omistajan profiiliWolfgang Wienand↗
Lonza Group AG, founded in 1897, is a Swiss multinational company specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition industries. Headquartered in Basel, Switzerland, Lonza operates over 30 sites across Europe, North America, and Asia, employing approximately 18,000 people. The company offers a comprehensive range of services, including the development and manufacturing of biopharmaceuticals, small molecules, cell and gene therapies, and health ingredients. Lonza's mission is to transform customers' breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. The company is recognized as a pioneer and world leader in the contract development and manufacturing organization (CDMO) industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. In 2023, Lonza reported revenues of CHF 3.6 billion and a CORE EBITDA of CHF 1.1 billion.
Omistajan profiiliWolfgang Wienand↗
Lonza Group AG, founded in 1897, is a Swiss multinational company specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition industries. Headquartered in Basel, Switzerland, Lonza operates over 30 sites across Europe, North America, and Asia, employing approximately 18,000 people. The company offers a comprehensive range of services, including the development and manufacturing of biopharmaceuticals, small molecules, cell and gene therapies, and health ingredients. Lonza's mission is to transform customers' breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. The company is recognized as a pioneer and world leader in the contract development and manufacturing organization (CDMO) industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. In 2023, Lonza reported revenues of CHF 3.6 billion and a CORE EBITDA of CHF 1.1 billion.
Omistajan profiiliWolfgang Wienand↗
Bayer AG is a German multinational corporation specializing in pharmaceuticals, consumer health, crop science, and animal health. Founded in 1863, it has grown into one of the world's largest pharmaceutical and biotechnology companies. Its key products include prescription medications, over-the-counter drugs, and agricultural solutions such as pesticides and seeds. With a global presence, Bayer operates in over 100 countries, serving millions of customers worldwide. The company's mission, 'Health for all, Hunger for none,' reflects its commitment to improving health and nutrition globally. Under the leadership of CEO Bill Anderson, appointed in June 2023, Bayer is undergoing a significant transformation to enhance innovation and operational efficiency.
Omistajan profiiliBill Anderson↗
Bayer AG is a German multinational corporation specializing in pharmaceuticals, consumer health, crop science, and animal health. Founded in 1863, it has grown into one of the world's largest pharmaceutical and biotechnology companies. Its key products include prescription medications, over-the-counter drugs, and agricultural solutions such as pesticides and seeds. With a global presence, Bayer operates in over 100 countries, serving millions of customers worldwide. The company's mission, 'Health for all, Hunger for none,' reflects its commitment to improving health and nutrition globally. Under the leadership of CEO Bill Anderson, appointed in June 2023, Bayer is undergoing a significant transformation to enhance innovation and operational efficiency.
Omistajan profiiliBill Anderson↗
Company profile is currently being completed.
Omistajan profiiliAlbert Bourla↗
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. Founded in 1849, the company develops and produces a wide range of medicines and vaccines across various therapeutic areas.
Omistajan profiiliAlbert Bourla↗